Gene, Cell and ASO therapies are changing the lives of patients and families devastated by rare diseases. These medicines offer the remarkable hope of a life-saving, potentially curative treatment for previously untreatable diseases. And with 2,500+ trials in the pipeline and a growth rate of 25% per year, this industry is poised to revolutionize medicine.
However, these high-cost, ultra-rare therapies also pose unique challenges for payers across the world when it comes to coverage and reimbursement. Without a payment solution as innovative as the cures themselves, we anticipate patient access becoming a structural issue within 2-3 years, with the burden ultimately falling upon patients and families.
Gene, Cell and ASO therapies are savings lives, but limited to those who can afford them
New gene and cell therapies pose significant pricing risk to health plans that existing actuarial methods aren't equipped to handle
Getting payers to cover a new therapy is the most time-intensive and frictional part of a treatment's go-to market process
Former Lead Data Scientist, Oscar Health
Former President and CEO, AIG
Former CFO, J.P. Morgan
Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management
Ford Professor of Economics at MIT
Associate Professor, Markets, Public Policy, and Law at Boston University
Former CCO, bluebird bio
Former Assistant Attorney General of the United States
Chairman and CEO, SiriusPoint
Co-founder and CEO, Oscar Health